Still Disease
11
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
18%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (11)
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
Clinical Autoinflammatory Disease Cohort
AutoInflammatory Disease Alliance Registry (AIDA)
Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases